LY3541860

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

HealthyMultiple SclerosisRheumatoid Arthritis

Phase 1

A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants

CompletedNCT05042310

Eli Lilly and CompanyHealthy

Start: 2021-11-11End: 2023-12-27Updated: 2024-04-05

Phase 2

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Active, not recruitingNCT06220669

Eli Lilly and CompanyMultiple Sclerosis

Start: 2024-03-19End: 2026-07-01Updated: 2026-04-07

A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

TerminatedNCT06859294

Eli Lilly and CompanyRheumatoid Arthritis

Start: 2025-03-19End: 2026-06-05Updated: 2026-06-17